$COSM

Cosmos Health Inc.

Cosmos Health is a healthcare group headquartered in Thessaloniki, Greece. It develops, manufactures and sells generic medicines, pharmaceutical products, nutraceuticals and biocides. Its proprietary brands include Sky Premium Life and Mediterranation nutraceuticals, and C-Sept and C-Scrub biocides and antiseptic soaps. It also manufactures healthcare products for third parties. As a pharmaceutical wholesaler, Cosmos Health distributes prescription and over-the-counter medicines, medical devices, supplements and other healthcare products to pharmacies, hospitals, clinics and other distributors. Its ZipDoctor platform provides subscription-based telehealth services directly to consumers in the United States. The company also researches medicines and uses its Cloudscreen platform to identify potential new uses for existing drugs.

0
1
0

No SEC Form 4 filings for $COSM in the last 30 days.

See all $COSM insider activity →
Low

Cosmos Health (COSM) Reports $1.83M Monthly Subscription Value

Cosmos Health (COSM) reported $1.83M in monthly subscription value for October, equivalent to $22.0M annualized, and $1.67M in U.S. e-commerce sales, including $1.02M from subscriptions. The data is preliminary and unaudited, with no prior-period comparison provided.

COSM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning COSM (Cosmos Health Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent COSM coverage spans financial news and earnings.

What's driving COSM

AlphAI scores every news story that mentions COSM with an AI model for sentiment and relevance, and aggregates insider trades from Cosmos Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $COSM

Score

Monthly subscription value nearly doubled to almost $1.8 million at Cosmos Health

Cosmos Health Inc. (NASDAQ: COSM) reported rapid growth in its U.S. direct-to-consumer subscription business, with active subscriptions rising to 12,050 and monthly subscription value nearly doubling to almost $1.8 million. The company attributes this growth to its recurring revenue model and plans to expand the subscription service globally. CEO Greg Siokas highlighted the value of recurring revenue and the company's expansion into the Oceania region.

Noble Capital initiates Cosmos Health stock with outperform rating

Noble Capital initiated coverage on Cosmos Health (NASDAQ: COSM) with an outperform rating and a $1.40 price target, citing potential profitability improvements from higher-margin products. The stock is currently at $0.26, down 74% over the past year. The firm highlights the company's wholesale distribution and expanding U.S. direct-to-consumer operations as growth drivers.

$COSMLowGuidance· initiate · $15M

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S.…

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days · Q4 2026 U.S. revenue: approximately $15 million e

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Cosmos Health Inc. (NASDAQ: COSM) reported record revenue growth in 2026, with preliminary nine-month revenue of $54.3 million, up 19% year-over-year. CEO Greg Siokas highlighted strong performance across all business segments, including a rapidly growing U.S. direct-to-consumer subscription model and a sixfold increase in contract manufacturing pipeline. The company expects full-year 2026 revenue to exceed $74 million, with significant contributions from both established and new segments.

Related tickers